• 1
    Young RC, Ozol RF, Myers CE: The anthracycline antineoplastic drugs. N Engl J Med 1981; 305: 139153
  • 2
    van Hoff DD, Layard MW, Basa P, Davis HL Jr, von Hoff AL, Rozencweig M, Muggia FM: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710717
  • 3
    Choen M, Kronzon I, Lebowitz A: Reversible doxorubicin-induced congestive heart failure. Arch Intern Med 1982; 142: 15701571
  • 4
    Saini J, Rich MW, Lyss AP: Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity. Report of three cases. Ann Intern Med 1987; 106: 814816
  • 5
    Gianni L, Corden BJ, Myers CE: The biochemical of anthracycline toxicity and anti tumoral activity. In Reviews in Biochemical Toxicology (Eds. HodgsonE, PhilportRM), p. 182. Amsterdam: Elsevier, 1983
  • 6
    Doroshow JH: Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 1983; 43: 460472
  • 7
    Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 13491355
  • 8
    Yue TL, Cheng HY, Lysko PG, McKenna PJ, Feuerstein R, Gu JL, Lysko KA, Davis LL, Feuerstein G: Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992; 263: 9298
  • 9
    Bril A, Slivjak M, Di Martino MJ, Feuerstein GZ, Linee P, Poyser RH, Ruffolo RR Jr, Smith EF : Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetized minipigs: Comparison with propranolol. Cardiovasc Res 1992; 26: 518525